Age: 57.0
Sex: M
Vaccine: COVID19, COVID19, COVID19, COVID19
Symptoms: COVID-19 immunisation, Suspected COVID-19
Clinical narrative: REVACCINATION WITH DIFFERENT COVID-19 VACCINE; SUSPECTED COVID-19 INFECTION; This spontaneous report received from a patient via other manufacturer (Pfizer) concerned a 58 year old male. The patient's height, and weight were not reported. The patient's concurrent conditions included: allergies (not specified) and asthma. The patient received covid-19 vaccine ad26.cov2.s (Dose number in series 1) (suspension for injection, route of admin not reported, batch number: 042A21A, expiry: unknown) dose was not reported, 1 total administered on 08-APR-2021 at right arm for covid-19 prophylaxis. Age at time of vaccination 57 years old.  It was unknown whether patient had any adverse events following vaccination with first dose of covid-19 vaccine ad26.cov2.s (Dose number in series 1). The patient received second dose of non-company suspect vaccine included: Moderna covid-19 vaccine (elasomeran) (Dose number in series 2) (form of admin, route of admin was not reported, batch number: 021C21A, expiry: unknown) dose and frequency were not reported, administered on 05-NOV-2021 at right arm for covid-19 prophylaxis.  It was unknown whether patient had any adverse events following vaccination with Moderna covid-19 vaccine (Dose number in series 2). The patient received third dose of non-company suspect vaccine included: Pfizer biontech covid-19 vaccine (tozinameran) (Dose number in series 3) (form of admin, route of admin was not reported, batch number: FP7150, expiry: unknown) dose and frequency were not reported, administered on 20-AUG-2022 at right arm for covid-19 prophylaxis.  It was unknown whether patient had any adverse events following vaccination with Pfizer biontech covid-19 vaccine (Dose number in series 3). The patient received fourth dose of non-company suspect vaccine included: Moderna covid-19 vaccine (bivalent) (elasomeran) (Dose number in series 4) (form of admin, route of admin was not reported, batch number: 023H22A, expiry: unknown) dose and frequency were not reported, administered on 06-DEC-2022 at right arm for covid-19 prophylaxis which was revaccination with different covid-19 vaccine (Dose number in series 4). Concomitant medications included Astepro (azelastine hydrochloride), Allegra (fexofenadine hydrochloride) and Flonase (fluticasone propionate).  On an unspecified date in DEC-2022, the patient experienced suspected covid-19 infection (Dose number in series 4). The patient received non-company suspect drug Paxlovid (form of admin and route of admin was not reported, batch number and expiry date was not reported) dose and frequency were not reported administered from 13-DEC-2022 to 17-DEC-2022 for covid-19 treatment. On 23-DEC-2022, the patient was sick again (Dose number in series 4). The patient recovered from sick again on 01-JAN-2023.  The action taken with covid-19 vaccine ad26.cov2.s, elasomeran, tozinameran, elasomeran was not applicable and for paxlovid was drug withdrawn. The patient recovered from suspected covid-19 infection on 01-JAN-2023, and the outcome of revaccination with different covid-19 vaccine was not reported. This report was non-serious.